Semavic®
ning uch ta’sirini
o’zingiz uchun kashf eting

Ta’sir etuvchi modda: semaglutid

Semavic® jiddiy yurak-qon tomir kasalliklari xavfini kamaytiradi^{(1) Semavic® dori vositasini tibbiy qo’llash bo’yicha ko’rsatmalar}
Semavic® triglitserid va xolesterin darajasini pasaytiradi^{(1) Semavic® dori vositasini tibbiy qo’llash bo’yicha ko’rsatmalar}
Semavic® sistolik qon bosimini pasaytiradi^{(1) Semavic® dori vositasini tibbiy qo’llash bo’yicha ko’rsatmalar}

Batafsil ma’lumot oling

Semavic® 2-toifa qandli diabet (qon plazma glyukozasi va glyukozalangan gemoglobin (HbA1c)) bo’lgan kattalarda qondagi glyukoza darajasini pasaytiradi^{(1) Semavic® dori vositasini tibbiy qo’llash bo’yicha ko’rsatmalar}

Batafsil ma’lumot oling

Semavic® ishtahani bostiradi va kun davomida kaloriya iste’molini 18–35 % ga kamaytiradi^{(1) Semavic® dori vositasini tibbiy qo’llash bo’yicha ko’rsatmalar}
Semavic® asosan yog’ massasini kamaytirish orqali tana vaznini kamaytiradi^{(1) Semavic® dori vositasini tibbiy qo’llash bo’yicha ko’rsatmalar}

Batafsil ma’lumot oling

Semavic®ning ta’sir etuvchi moddasi inson organizmida ishlab chiqariladigan va insulin sekretsiyasini tartibga soluvchi glyukagonga o’xshash peptid-1 ning muqobili bo’lgan semaglutiddir.

Semaglutidning ta’sir doirasi

MIYA

↓

Oziq-ovqat iste’moli ^{(7)
Bagger JI, et al. Clin Endocrinol Metab 2015}

↑

Toʻyinganlik ^{(8)
Flint A, et al. J Clin Invest 1998} ^{(9)
Устный доклад 23-OR на 76-м научном заседании Американской диабетической
ассоциации}

↑

Neyroproteksiya ^{(2)
Campbell JE, DJ Drucker. Cell Metab 2013}

OSHQOZON

↓

Oshqozonni bo’shatish ^{(2)
Campbell JE, DJ Drucker. Cell Metab 2013} ^{(10)
Tong J, D'Alessio D. Diabetes 2014}

JIGAR

↓

Endogen glyukoza
ishlab chiqarish ^{(11)
Armstrong MJ, et al. J Hepatol 2016}

↑

Jigar insulin
sezuvchanligi ^{(11)
Armstrong MJ, et al. J Hepatol 2016}

↓

de novo lipogenezi ^{(11)
Armstrong MJ, et al. J Hepatol 2016}

↓

Steatoz ^{(12)
Armstrong MJ, et al. Lancet 2016}

Tana massasi

↓

Yog ’massasi ^{(1)
Semavic® dori vositasini tibbiy qo’llash bo’yicha ko’rsatmalar}

BUYRAKLAR

↓

Disfunktsiya xavfi ^{(13)
Semaglutide and cardiovascular outcomes in patients with type 2
diabetes}

OSHQOZONOSTI BEZI

↑

Beta-hujayra funktsiyasi ^{(2)
Campbell JE, DJ Drucker. Cell Metab 2013}

↓

Beta hujayra apoptozi ^{(2)
Campbell JE, DJ Drucker. Cell Metab 2013}

↑

Insulin biosintezi ^{(2)
Campbell JE, DJ Drucker. Cell Metab 2013}

↓

Glyukozaga bog’liq
insulin sekretsiyasi ^{(2)
Campbell JE, DJ Drucker. Cell Metab 2013}

↓

Glyukozaga bog’liq
glyukagon sekretsiyasi ^{(2)
Campbell JE, DJ Drucker. Cell Metab 2013}

YURAK

↓

Yurak-qon tomir xavfi ^{(3)
Marso SP, et al. N Engl J Med 2016}

↑

Yurak funktsiyasi ^{(2)
Campbell JE, DJ Drucker. Cell Metab 2013}

↓

Sistolik
qon bosimi ^{(4)
Ryan D, Acosta A. Obesity 2015}

↓

Yallig’lanish ^{(5)
Hogan AE, et al. Diabetologia 2014}

Tana massasi

↓

Yog ’massasi ^{(1)
Semavic® dori vositasini tibbiy qo’llash bo’yicha ko’rsatmalar}

MIYA

↓

Oziq-ovqat iste’moli ^{(7)
Bagger JI, et al. Clin Endocrinol Metab 2015}

↑

Toʻyinganlik ^{(8)
Flint A, et al. J Clin Invest 1998} ^{(9)

Устный доклад 23-OR на 76-м научном заседании Американской диабетической ассоциацииTong J, D'Alessio
D. Diabetes 2014}

↑

Neyroproteksiya ^{(2)
Campbell JE, DJ Drucker. Cell Metab 2013}

OSHQOZONOSTI BEZI

↑

Beta-hujayra funktsiyasi ^{(2)
Campbell JE, DJ Drucker. Cell Metab 2013}

↓

Beta hujayra apoptozi ^{(2)
Campbell JE, DJ Drucker. Cell Metab 2013}

↑

Insulin biosintezi ^{(2)
Campbell JE, DJ Drucker. Cell Metab 2013}

↓

Glyukozaga bog’liq
insulin sekretsiyasi ^{(2)
Campbell JE, DJ Drucker. Cell Metab 2013}

↓

Glyukozaga bog’liq
glyukagon sekretsiyasi ^{(2)
Campbell JE, DJ Drucker. Cell Metab 2013}